



VGX Gene Therapy Technology Featured at the 90th Annual Endocrine Society Meeting

Blue Bell, PA – June 17, 2008 –

VGX Pharmaceuticals Inc. (VGX) and its affiliate, VGX Animal Health Inc. (VGXAH), announced today that the Company's gene therapy technology for dogs with cancer was presented at the Endocrine Society's 90th Annual Meeting. The Meeting takes place June 15-18, 2008 in San Francisco, CA. The abstract of this technology was selected for a special media presentation highlighting "Frontier Research and Exciting Results" as part of a live webcast on June 16.

Dr. Ruxandra Draghia-Akli, the Company's Vice President of Research, addressed the media and presented the summary research findings in a presentation titled "Companion Dogs: Helping our Helpers". The archived webcast can be viewed at <http://www.webcastcanada.ca/endo/june16-2.php>

The subject technology utilizes a non-viral DNA molecule encoding for growth hormone-releasing hormone (GHRH) as a potential therapy for cancer cachexia, also known as wasting syndrome. VGX researchers tested the gene therapy in 55 companion dogs that had cancer and anemia and were receiving cancer treatment. Three months after the injection, 54 percent of the dogs had responded to the therapy as revealed by blood tests. Dogs that responded to the therapy survived 84 percent longer, compared with dogs that did not respond to it and untreated control dogs that received a placebo injection.

The study has implications for treating cachexia associated with human cancers because dogs with spontaneous malignancies serve as good models for human disease. VGX Pharmaceuticals is awaiting approval from the Food and Drug Administration to study the GHRH treatment (VGX-3200) in humans. VGX Animal Health also plans to develop the GHRH technology for companion animals including dogs and cats, and already has a product approved for pigs in Australia (LifeTide™ SW 5).

Further information on the research can be found in the Endocrine Society's news release at <http://www.endo-society.org/media/ENDO-08/news/Gene-therapy-improves-survival.cfm>

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, PENNVAX™-B for HIV infection, which is in 2 separate Phase I clinical trials, and VGX-1027 for inflammatory diseases, which is in Phase I clinical trials. In addition, the Company has filed INDs for VGX-3100, a DNA therapeutic vaccine for cervical cancer; VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia; and VGX-3400, a DNA preventative vaccine for avian influenza. VGX has established a vertically-integrated DNA Vaccines and Therapies Platform with extensive capabilities including SynCon™ DNA-based product candidates, the CELLECTRA® delivery device, and efficient cGMP plasmid manufacturing capabilities. Vertical control over key aspects of product development has enabled the Company to consistently develop multiple product candidates, from bench-to-IND filing, within 1 year. The

product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

About VGX Animal Health

VGX Animal Health, Inc. was formed in 2007 as a majority-owned subsidiary of VGX Pharmaceuticals, Inc. (VGXP) specializing in animal health therapeutics. VGXAH's products and technology were initially developed by ADViSYS Inc, which was founded in 1997 and acquired by VGX Pharmaceuticals in early 2007. VGXAH's lead product, LifeTide™ SW 5, was approved in Australia in January 2008. The product is an injectable plasmid encoding for porcine Growth Hormone Release Hormone ("GHRH"). In addition, the Company has conducted extensive pre-clinical trials for other applications of its proprietary plasmid-based GHRH therapy in both food and companion animals. Treatment of cancer cachexia, anemia, and improved milk production are just a few of the many potential applications of this technology in animal health. VGXAH's product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGXAH can be found at www.vgxah.com.

Company Contact:

Kevin W. Rassas
Senior Vice-President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com